FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 151 filers reported holding FATE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.11 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,997,080 | -52.6% | 1,523,500 | +6.0% | 0.01% | -54.2% |
| Q1 2024 | $10,552,718 | +50.3% | 1,437,700 | -23.4% | 0.02% | +50.0% |
| Q4 2023 | $7,019,606 | +71.3% | 1,876,900 | -2.9% | 0.02% | +60.0% |
| Q3 2023 | $4,097,536 | -52.6% | 1,932,800 | +6.4% | 0.01% | -54.5% |
| Q2 2023 | $8,650,348 | -18.9% | 1,817,300 | -2.9% | 0.02% | -21.4% |
| Q1 2023 | $10,663,560 | +55.8% | 1,870,800 | +175.8% | 0.03% | +47.4% |
| Q4 2022 | $6,845,056 | +523.4% | 678,400 | +1284.5% | 0.02% | +533.3% |
| Q3 2022 | $1,098,000 | -7.7% | 49,000 | +2.1% | 0.00% | 0.0% |
| Q2 2022 | $1,189,000 | -58.8% | 48,000 | -35.6% | 0.00% | -62.5% |
| Q1 2022 | $2,888,000 | -80.5% | 74,500 | -70.5% | 0.01% | -78.4% |
| Q4 2021 | $14,780,000 | -44.1% | 252,600 | -43.4% | 0.04% | -46.4% |
| Q3 2021 | $26,434,000 | -58.4% | 446,000 | -39.1% | 0.07% | -58.9% |
| Q2 2021 | $63,530,000 | -6.5% | 732,000 | -11.2% | 0.17% | -10.2% |
| Q1 2021 | $67,931,000 | +24.9% | 823,900 | +37.7% | 0.19% | +29.0% |
| Q4 2020 | $54,401,000 | +264.8% | 598,269 | +60.4% | 0.14% | +237.2% |
| Q3 2020 | $14,913,000 | +181.2% | 373,100 | +141.3% | 0.04% | +168.8% |
| Q2 2020 | $5,304,000 | +227.2% | 154,600 | +111.8% | 0.02% | +166.7% |
| Q1 2020 | $1,621,000 | -47.0% | 73,000 | -53.3% | 0.01% | -14.3% |
| Q4 2019 | $3,057,000 | -6.1% | 156,200 | -25.4% | 0.01% | -12.5% |
| Q3 2019 | $3,254,000 | -37.8% | 209,500 | -18.7% | 0.01% | -38.5% |
| Q2 2019 | $5,231,000 | -11.4% | 257,700 | -23.3% | 0.01% | -13.3% |
| Q1 2019 | $5,905,000 | +29.0% | 336,100 | -5.8% | 0.02% | +25.0% |
| Q4 2018 | $4,576,000 | -2.8% | 356,700 | +23.4% | 0.01% | +9.1% |
| Q3 2018 | $4,708,000 | +106.5% | 289,000 | +43.7% | 0.01% | +83.3% |
| Q2 2018 | $2,280,000 | +35.2% | 201,100 | +16.4% | 0.01% | +20.0% |
| Q1 2018 | $1,686,000 | +286.7% | 172,700 | +141.9% | 0.01% | +400.0% |
| Q4 2017 | $436,000 | +451.9% | 71,400 | +257.0% | 0.00% | – |
| Q3 2017 | $79,000 | – | 20,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $11,083,330 | 2.77% |
| Redmile Group, LLC | 13,169,057 | $43,194,507 | 2.61% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 497,360 | $1,631,341 | 2.06% |
| Boxer Capital, LLC | 8,215,910 | $26,948,185 | 1.42% |
| Deep Track Capital, LP | 5,572,607 | $18,278,151 | 0.55% |
| Vestal Point Capital, LP | 2,000,000 | $6,560,000 | 0.49% |
| Bruce & Co., Inc. | 300,000 | $984,000 | 0.32% |
| Octagon Capital Advisors LP | 520,800 | $1,708,224 | 0.27% |
| Integral Health Asset Management, LLC | 850,000 | $2,788,000 | 0.26% |
| Bellevue Group AG | 4,839,779 | $15,874,475 | 0.26% |